HIV mutation literature information.


  Viral Genetic Diversity and Polymorphisms in a Cohort of HIV-1-Infected Patients Eligible for Initiation of Antiretroviral Therapy in Abuja, Nigeria.
 PMID: 25582324       2015       AIDS research and human retroviruses
Result: Among all the mutations detected, T74S (54.5%) in PR and E138A (17%), V179I (16%), followed by V118I
Discussion: Subtype G, CRF43-02G, and CRF06-cpx viruses utilized the codon GTG/GTA to encode valine and more likely to develop V179E mutations, whereas other CRF viruses are biased toward V179I and V179D.
Discussion: This pattern of amino acid substitution by a single nucleotide change is called quasisynonymy; it may explain the high rate of the V179E found in subtype G and CRF06-cpx in this cohort and is concordant with published data and statistics predicting the occurrence of this mutation at RT position 179 of these viruses.


  HIV-1 transmitted drug resistance-associated mutations and mutation co-variation in HIV-1 treatment-naive MSM from 2011 to 2013 in Beijing, China.
 PMID: 25510523       2014       BMC infectious diseases
Abstract: Fifty-seven samples had at least one TDR-associated mutation, mainly including L10I/V (6.3%), A71L/T/V (6.3%), V179D/E (5.4%), and V106I (2.7%), with different distributions of TDR-associated mutations by different HIV-1 subtypes and by each year.
Abstract: Moreover, eight significant co-variation pairs were found between TDR-associated mutations (V179D/E) and seven overlapping polymorphisms in subtype CRF01_AE.
Result: PI mutations included


  Characteristics of HIV-1 natural drug resistance-associated mutations in former paid blood donors in Henan Province, China.
 PMID: 24586665       2014       PloS one
Result: V179D/E reduced NVP and EFV susceptibility by about 2-fold.
Result: V179E did not cause resistance to NNRTI.
Table: V179D/E


  Impact of Y181C and/or H221Y mutation patterns of HIV-1 reverse transcriptase on phenotypic resistance to available non-nucleoside and nucleoside inhibitors in China.
 PMID: 24885612       2014       BMC infectious diseases
Discussion: At the same time, the double mutations were observed along with other NNRTIs including K101E, K101Q, V179D, V179E, K103N, and the viruses were predominant in quasispecies of 6 HIV-1 infected patients in a drug resistance surveillance cohort.


  The prevalence of transmitted HIV drug resistance among MSM in Anhui province, China.
 PMID: 25035709       2014       AIDS research and therapy
Result: T69A/N/S, V179E and P236L were polymorphism mutations against RTIs.
Discussion: A98G and V179E were excluded from the WHO list of SDRMs because of high occurrence in viruses from treatment-naive individuals.
Discussion: Other commonly observed mutations were T69A/N/S, V179E, L10I/L/V, V11I/V, L33F, and A71A/T/V; none of these mutations is known to confer drug resistance to NRTIs, NNRTIs, or PIs.


  The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults.
 PMID: 24157905       2013       AIDS (London, England)
Abstract: Polymorphisms at codon 179, especially V179D/E/T, predicted reduced week 4 responses (P = 0.001) but not virologic failure.
Abstract: The mechanisms underlying the slower suppression seen with V179D/E/T deserve further investigation.


  Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens.
 PMID: 23840622       2013       PloS one
Result: Additional NNRTI-resistance mutations not shown in Table 4 included (i) A98G, which occurred in 3.3% of NNRTI-treated patients; (ii) V106A, which occurred in 0.6% of NNRTI-treated patients; (iii) E138G/Q, which occurred in 0.9% and 0.9% of patients, respectively; (iv) V179D/E/T/F, which occurred in 8.5%, 0.7%, 0.5%, and 0% of NNRTI-treated patients respectively; (v) Y181I/V, which occurred in one and no patient, respectively; (vi) H221Y, which occurred in 5.9% of EFV-treated and 9.3% of NVP-treated patients (p<0.001); (vii) P225H, which occurred in 13.6% of EFV-treate


  Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes.
 PMID: 23629015       2013       The Journal of antimicrobial chemotherapy
Abstract: For etravirine, only G190A was more prevalent in B than non-B subtypes, whereas V90I and V179E were more frequent in non-B than B subtypes.


  Impact of Novel Resistance Profiles in HIV-1 Reverse Transcriptase on Phenotypic Resistance to NVP.
 PMID: 22536497       2012       AIDS research and treatment
Introduction: This type of mutation consists of A98G, K101Q, V108I, and V179D/E.


  HIV-1 subtype D infections among Caucasians from Northwestern Poland--phylogenetic and clinical analysis.
 PMID: 22359615       2012       PloS one
Table: V179E



Browser Board

 Co-occurred Entities




   Filtrator